9,118 United Therapeutics Corporation $UTHR Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp lowered its position in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 5.8% during the third quarter, Holdings Channel.com reports. The institutional investor owned 149,066 shares of the biotechnology company’s stock after selling 9,118 shares during the period. Fifth Third Bancorp’s holdings in United Therapeutics were worth $80,778,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Arjuna Capital lifted its stake in United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after acquiring an additional 18 shares during the period. Abacus Wealth Partners LLC boosted its holdings in shares of United Therapeutics by 5.6% in the 3rd quarter. Abacus Wealth Partners LLC now owns 396 shares of the biotechnology company’s stock valued at $215,000 after acquiring an additional 21 shares during the last quarter. Bryn Mawr Trust Advisors LLC boosted its holdings in shares of United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 24 shares during the last quarter. Parallel Advisors LLC increased its stake in shares of United Therapeutics by 2.1% in the third quarter. Parallel Advisors LLC now owns 1,154 shares of the biotechnology company’s stock worth $625,000 after acquiring an additional 24 shares during the period. Finally, Meeder Advisory Services Inc. increased its stake in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after acquiring an additional 26 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent research reports. Leerink Partners raised their target price on shares of United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a report on Monday, October 19th. Royal Bank Of Canada upped their price target on shares of United Therapeutics from $697.00 to $725.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $728.00 price target on shares of United Therapeutics in a report on Wednesday, October 14th. UBS Group set a $725.00 price target on United Therapeutics in a research report on Monday, October 19th. Finally, Raymond James Financial set a $720.00 price objective on United Therapeutics in a research note on Wednesday, November 4th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $676.40.

Get Our Latest Analysis on United Therapeutics

Insider Activity

In related news, CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Monday, August 31st. The shares were sold at an average price of $511.09, for a total transaction of $4,855,355.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $165,819,572.87. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders have sold 412,238 shares of company stock valued at $220,975,006. Insiders own 8.60% of the company’s stock.

United Therapeutics Trading Down 0.4%

Shares of NASDAQ:UTHR opened at $593.31 on Friday. United Therapeutics Corporation has a 12-month low of $455.63 and a 12-month high of $614.23. The business has a 50 day moving average of $540.58 and a two-hundred day moving average of $535.80. The company has a market capitalization of $25.27 billion, a PE ratio of 22.39, a PEG ratio of 3.99 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). The firm had revenue of $832.50 million for the quarter, compared to analyst estimates of $781.14 million. United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. United Therapeutics’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period in the previous year, the business earned $7.16 EPS. Equities research analysts predict that United Therapeutics Corporation will post 24.90 earnings per share for the current fiscal year.

United Therapeutics declared that its board has authorized a share repurchase program on Thursday, October 22nd that allows the company to repurchase $2 billion in outstanding shares. This repurchase authorization allows the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Share repurchase programs are often an indication that the company’s board of directors believes its shares are undervalued.

Top United Therapeutics Stories

Here are a few of the latest stories about UTHR:

  • Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target. Its forecasts point to rising EPS, from $27.46 in FY2026 to $53.67 in FY2030, suggesting expectations for substantial longer-term earnings growth. HC Wainwright coverage article
  • Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for about $5.64 million, reducing her direct stake by 2.84%; she still owns about 324,443 shares. Director Christopher Patusky also sold 1,210 shares for $701,800, a 36.12% reduction in his position. Insider selling can create a near-term sentiment overhang, although it does not by itself indicate a change in the company’s outlook. CEO sale report Director sale report

United Therapeutics Company Profile

(Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.

Read More

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.